Literature DB >> 22312126

TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis.

Karel Otero1, Masahiro Shinohara, Haibo Zhao, Marina Cella, Susan Gilfillan, Angela Colucci, Roberta Faccio, F Patrick Ross, Steve L Teitelbaum, Hiroshi Takayanagi, Marco Colonna.   

Abstract

TREM2 is an immunoreceptor expressed on osteoclasts (OC) and microglia that transmits intracellular signals through the adaptor DAP12. Individuals with genetic mutations inactivating TREM2 or DAP12 develop the Nasu-Hakola disease (NHD) with cystic-like lesions of the bone and brain demyelination that lead to fractures and presenile dementia. The mechanisms of this disease are poorly understood. In this study, we report that TREM2-deficient mice have an osteopenic phenotype reminiscent of NHD. In vitro, lack of TREM2 impairs proliferation and β-catenin activation in osteoclast precursors (OcP) in response to M-CSF. This defect results in accelerated differentiation of OcP into mature OC. Corroborating the importance of a balanced proliferation and differentiation of OcP for bone homeostasis, we show that conditional deletion of β-catenin in OcP also results in reduced OcP proliferation and accelerated osteoclastogenesis in vitro as well as osteopenia in vivo. These results reveal that TREM2 regulates the rate of osteoclastogenesis and provide a mechanism for the bone pathology in NHD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22312126      PMCID: PMC3732181          DOI: 10.4049/jimmunol.1102836

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts.

Authors:  J Paloneva; M Kestilä; J Wu; A Salminen; T Böhling; V Ruotsalainen; P Hakola; A B Bakker; J H Phillips; P Pekkarinen; L L Lanier; T Timonen; L Peltonen
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

2.  Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis.

Authors:  Takako Koga; Masanori Inui; Kazuya Inoue; Sunhwa Kim; Ayako Suematsu; Eiji Kobayashi; Toshio Iwata; Hiroshi Ohnishi; Takashi Matozaki; Tatsuhiko Kodama; Tadatsugu Taniguchi; Hiroshi Takayanagi; Toshiyuki Takai
Journal:  Nature       Date:  2004-04-15       Impact factor: 49.962

3.  The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase.

Authors:  Attila Mócsai; Mary Beth Humphrey; Jessica A G Van Ziffle; Yongmei Hu; Andrew Burghardt; Steven C Spusta; Sharmila Majumdar; Lewis L Lanier; Clifford A Lowell; Mary C Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-08       Impact factor: 11.205

Review 4.  Osteoimmunology: cytokines and the skeletal system.

Authors:  Seoung-Hoon Lee; Tae-Soo Kim; Yongwon Choi; Joseph Lorenzo
Journal:  BMB Rep       Date:  2008-07-31       Impact factor: 4.778

5.  RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.

Authors:  Uma Sankar; Krupen Patel; Thomas J Rosol; Michael C Ostrowski
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

6.  The signaling adapter protein DAP12 regulates multinucleation during osteoclast development.

Authors:  Mary Beth Humphrey; Kouetsu Ogasawara; Wei Yao; Steven C Spusta; Michael R Daws; Nancy E Lane; Lewis L Lanier; Mary C Nakamura
Journal:  J Bone Miner Res       Date:  2003-12-16       Impact factor: 6.741

7.  Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype.

Authors:  Juha Paloneva; Tuula Manninen; Grant Christman; Karine Hovanes; Jami Mandelin; Rolf Adolfsson; Marino Bianchin; Thomas Bird; Roxana Miranda; Andrea Salmaggi; Lisbeth Tranebjaerg; Yrjö Konttinen; Leena Peltonen
Journal:  Am J Hum Genet       Date:  2002-06-21       Impact factor: 11.025

8.  Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice.

Authors:  Tomonori Kaifu; Jin Nakahara; Masanori Inui; Kenichi Mishima; Toshihiko Momiyama; Mitsuji Kaji; Akiko Sugahara; Hisami Koito; Azusa Ujike-Asai; Akira Nakamura; Kiyoshi Kanazawa; Kyoko Tan-Takeuchi; Katsunori Iwasaki; Wayne M Yokoyama; Akira Kudo; Michihiro Fujiwara; Hiroaki Asou; Toshiyuki Takai
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

9.  DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features.

Authors:  Juha Paloneva; Jami Mandelin; Anna Kiialainen; Tom Bohling; Johannes Prudlo; Panu Hakola; Matti Haltia; Yrjo T Konttinen; Leena Peltonen
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

10.  Impaired differentiation of osteoclasts in TREM-2-deficient individuals.

Authors:  Marina Cella; Cecilia Buonsanti; Carey Strader; Takayuki Kondo; Andrea Salmaggi; Marco Colonna
Journal:  J Exp Med       Date:  2003-08-11       Impact factor: 14.307

View more
  71 in total

Review 1.  Notch and the regulation of osteoclast differentiation and function.

Authors:  Jungeun Yu; Ernesto Canalis
Journal:  Bone       Date:  2020-06-08       Impact factor: 4.398

Review 2.  TREM2 variants: new keys to decipher Alzheimer disease pathogenesis.

Authors:  Marco Colonna; Yaming Wang
Journal:  Nat Rev Neurosci       Date:  2016-02-25       Impact factor: 34.870

Review 3.  Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders.

Authors:  Todd E Golde
Journal:  Neuron       Date:  2019-03-20       Impact factor: 17.173

4.  TREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway.

Authors:  Honghua Zheng; Lin Jia; Chia-Chen Liu; Zhouyi Rong; Li Zhong; Longyu Yang; Xiao-Fen Chen; John D Fryer; Xin Wang; Yun-Wu Zhang; Huaxi Xu; Guojun Bu
Journal:  J Neurosci       Date:  2017-01-11       Impact factor: 6.167

5.  Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease.

Authors:  Taylor R Jay; Anna M Hirsch; Margaret L Broihier; Crystal M Miller; Lee E Neilson; Richard M Ransohoff; Bruce T Lamb; Gary E Landreth
Journal:  J Neurosci       Date:  2017-01-18       Impact factor: 6.167

6.  RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146.

Authors:  Yoshinori Matsumoto; Jose Larose; Oliver A Kent; Melissa Lim; Adele Changoor; Lucia Zhang; Yaryna Storozhuk; Xiaohong Mao; Marc D Grynpas; Feng Cong; Robert Rottapel
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

Review 7.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

8.  Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease.

Authors:  Margarita Giraldo; Francisco Lopera; Ashley L Siniard; Jason J Corneveaux; Isabelle Schrauwen; Julian Carvajal; Claudia Muñoz; Manuel Ramirez-Restrepo; Chris Gaiteri; Amanda J Myers; Richard J Caselli; Kenneth S Kosik; Eric M Reiman; Matthew J Huentelman
Journal:  Neurobiol Aging       Date:  2013-04-09       Impact factor: 4.673

9.  Phospholipase Cγ1 (PLCγ1) Controls Osteoclast Numbers via Colony-stimulating Factor 1 (CSF-1)-dependent Diacylglycerol/β-Catenin/CyclinD1 Pathway.

Authors:  Zhengfeng Yang; Seokho Kim; Sahil Mahajan; Ali Zamani; Roberta Faccio
Journal:  J Biol Chem       Date:  2016-12-09       Impact factor: 5.157

Review 10.  MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

Authors:  Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2017-11-07       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.